Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Iowa: - Saint Anthony Regional Hospital — Carroll, Iowa
- Blank Children's Hospital — Des Moines, Iowa
- Iowa Methodist Medical Center — Des Moines, Iowa
- UI Health Care Mission Cancer and Blood - Des Moines Clinic — Des Moines, Iowa
- Broadlawns Medical Center — Des Moines, Iowa
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic — Clive, Iowa
- Blank Children's Hospital — Des Moines, Iowa
- Iowa Methodist Medical Center — Des Moines, Iowa
Phase 3 Recruiting NIH
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06337318
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
- McFarland Clinic - Boone — Boone, Iowa
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
- Mercy Hospital — Cedar Rapids, Iowa
Phase 3 Recruiting Network
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in Iowa: - University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Iowa: - Research Site — Des Moines, Iowa
- Research Site — Iowa City, Iowa
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Iowa: - University of Iowa Hospitals and Clinics — Iowa City, Iowa
- Mission Cancer and Blood — Waukee, Iowa
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Iowa: - Blank Children's Hospital — Des Moines, Iowa
- University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
Phase 2 Recruiting NIH
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- McFarland Clinic - Trinity Cancer Center — Fort Dodge, Iowa
- McFarland Clinic - Jefferson — Jefferson, Iowa
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Mercy Hospital — Cedar Rapids, Iowa
- Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic — Clive, Iowa
- Mercy Medical Center - Des Moines — Des Moines, Iowa
Phase 2 Recruiting Network
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in Iowa: - University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
Phase 2 Recruiting Industry
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort A), and f…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06806033
Sites in Iowa: - Mission Blood and Cancer - MercyOne Cancer Center — Waukee, Iowa
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT05826535
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1, Phase 2 Recruiting Industry
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in Iowa: - University of Iowa Hospitals and Clinics — Iowa City, Iowa
Phase 2 Recruiting Industry
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibito…
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT07221500
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 2 Recruiting Industry
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have receive…
Sponsor: AstraZeneca
NCT ID: NCT06526793
Sites in Iowa: - Research Site — Iowa City, Iowa
- Research Site — Waukee, Iowa
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Iowa: - Mission Cancer + Blood — Waukee, Iowa
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Iowa: - University of Iowa-Holden Comprehensive Cancer Center ( Site 1017) — Iowa City, Iowa
Phase 2 Recruiting Industry
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Sponsor: March Biosciences Inc
NCT ID: NCT06534060
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1, Phase 2 Recruiting Industry
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Sponsor: AstraZeneca
NCT ID: NCT07109219
Sites in Iowa: - Research Site — Iowa City, Iowa
Phase 1 Recruiting Industry
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 unt…
Sponsor: Eli Lilly and Company
NCT ID: NCT07101328
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Sponsor: Kyowa Kirin, Inc.
NCT ID: NCT07192471
Sites in Iowa: - University of Iowa Health — Iowa City, Iowa
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
- Physicians' Clinic of Iowa PC — Cedar Rapids, Iowa
- Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
- Mercy Cancer Center-West Lakes — Clive, Iowa